NCT01066663: A reported trial by Dana-Farber Cancer Institute
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01066663 |
|---|---|
| Title | A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2010 |
| Completion date | Feb. 28, 2022 |
| Required reporting date | Feb. 28, 2023, midnight |
| Actual reporting date | April 4, 2022 |
| Date last checked at ClinicalTrials.gov | Nov. 14, 2025 |
| Days late | None |